(Total Views: 670)
Posted On: 08/22/2021 2:16:32 PM
Post# of 153903
Did Amarex blow it again?
For phase 2 of our Phase 1/2 mTNBC trial the only primary outcome is listed as follows.
Phase II: Progression free survival (PFS) defined as time in months from the date of first study treatment to the date of disease progression or death from any cause, whichever comes first. [ Time Frame: Every 6 to 9 weeks after study start, until progression or death, assessed up to 2 years after completion of treatment ]
So mOS was not included in a 2-year long study! Yet it's in mOS LL shows or has a promise of much better results than SG, let alone SOC while showing at best similar results as SG in PFS.
For phase 2 of our Phase 1/2 mTNBC trial the only primary outcome is listed as follows.
Phase II: Progression free survival (PFS) defined as time in months from the date of first study treatment to the date of disease progression or death from any cause, whichever comes first. [ Time Frame: Every 6 to 9 weeks after study start, until progression or death, assessed up to 2 years after completion of treatment ]
So mOS was not included in a 2-year long study! Yet it's in mOS LL shows or has a promise of much better results than SG, let alone SOC while showing at best similar results as SG in PFS.
(1)
(0)
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.
